Cargando…

Catheter ablation for treatment of patients with atrial fibrillation and heart failure: a meta-analysis of randomized controlled trials

BACKGROUND: There is a little evidence for the effects of catheter ablation (CA) on hard endpoints in patients with atrial fibrillation (AF) and heart failure (HF). METHODS: PubMed, Embase and Cochrane Library were searched for randomized controlled trials (RCTs) enrolling patients with AF and HF wh...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Yingxu, Bai, Fan, Qin, Fen, Li, Yixi, Tu, Tao, Sun, Chao, Zhou, Shenghua, Liu, Qiming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6090632/
https://www.ncbi.nlm.nih.gov/pubmed/30103676
http://dx.doi.org/10.1186/s12872-018-0904-3
_version_ 1783347222744662016
author Ma, Yingxu
Bai, Fan
Qin, Fen
Li, Yixi
Tu, Tao
Sun, Chao
Zhou, Shenghua
Liu, Qiming
author_facet Ma, Yingxu
Bai, Fan
Qin, Fen
Li, Yixi
Tu, Tao
Sun, Chao
Zhou, Shenghua
Liu, Qiming
author_sort Ma, Yingxu
collection PubMed
description BACKGROUND: There is a little evidence for the effects of catheter ablation (CA) on hard endpoints in patients with atrial fibrillation (AF) and heart failure (HF). METHODS: PubMed, Embase and Cochrane Library were searched for randomized controlled trials (RCTs) enrolling patients with AF and HF who were assigned to CA, rate control or medical rhythm control groups. This meta-analysis was performed by using random-effect models. RESULTS: Seven RCTs enrolling 856 participants were included in this meta-analysis. CA reduced the risks of all-cause mortality (risk ratio [RR] 0.52, 95% CI 0.35 to 0.76), HF readmission (RR 0.58, 95% CI 0.46 to 0.66) and the composite of all-cause mortality and HF readmission (RR 0.55, 95% CI 0.47 to 0.66) when compared with control. But there was no significant difference in cerebrovascular accident (RR 0.56, 95% CI 0.23 to 1.36) between two groups. Compared with control, CA was associated with improvement in left ventricular ejection fraction (mean difference [MD] 7.57, 95% CI 3.72 to 11.41), left ventricular end systolic volume (MD -14.51, 95% CI -26.84 to − 2.07), and left ventricular end diastolic volume (MD -3.78, 95% CI -18.51 to 10.96). Patients undergoing CA exhibited increased peak oxygen consumption (MD 3.16, 95% CI 1.09 to 5.23), longer 6-min walk test distance (MD 26.67, 95% CI 12.07 to 41.27), and reduced Minnesota Living with Heart Failure Questionnaire scores (MD -9.49, 95% CI -14.64 to − 4.34) than those in control group. Compared with control, CA was associated with improved New York Heart Association class (MD -0.74, 95% CI -0.83 to − 0.64) and lower B-type natriuretic peptide levels (MD -105.96, 95% CI -230.56 to 19.64). CONCLUSIONS: CA was associated with improved survival, morphologic changes, functional capacity and quality of life relative to control. CA should be considered in patients with AF and HF. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12872-018-0904-3) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6090632
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-60906322018-08-17 Catheter ablation for treatment of patients with atrial fibrillation and heart failure: a meta-analysis of randomized controlled trials Ma, Yingxu Bai, Fan Qin, Fen Li, Yixi Tu, Tao Sun, Chao Zhou, Shenghua Liu, Qiming BMC Cardiovasc Disord Research Article BACKGROUND: There is a little evidence for the effects of catheter ablation (CA) on hard endpoints in patients with atrial fibrillation (AF) and heart failure (HF). METHODS: PubMed, Embase and Cochrane Library were searched for randomized controlled trials (RCTs) enrolling patients with AF and HF who were assigned to CA, rate control or medical rhythm control groups. This meta-analysis was performed by using random-effect models. RESULTS: Seven RCTs enrolling 856 participants were included in this meta-analysis. CA reduced the risks of all-cause mortality (risk ratio [RR] 0.52, 95% CI 0.35 to 0.76), HF readmission (RR 0.58, 95% CI 0.46 to 0.66) and the composite of all-cause mortality and HF readmission (RR 0.55, 95% CI 0.47 to 0.66) when compared with control. But there was no significant difference in cerebrovascular accident (RR 0.56, 95% CI 0.23 to 1.36) between two groups. Compared with control, CA was associated with improvement in left ventricular ejection fraction (mean difference [MD] 7.57, 95% CI 3.72 to 11.41), left ventricular end systolic volume (MD -14.51, 95% CI -26.84 to − 2.07), and left ventricular end diastolic volume (MD -3.78, 95% CI -18.51 to 10.96). Patients undergoing CA exhibited increased peak oxygen consumption (MD 3.16, 95% CI 1.09 to 5.23), longer 6-min walk test distance (MD 26.67, 95% CI 12.07 to 41.27), and reduced Minnesota Living with Heart Failure Questionnaire scores (MD -9.49, 95% CI -14.64 to − 4.34) than those in control group. Compared with control, CA was associated with improved New York Heart Association class (MD -0.74, 95% CI -0.83 to − 0.64) and lower B-type natriuretic peptide levels (MD -105.96, 95% CI -230.56 to 19.64). CONCLUSIONS: CA was associated with improved survival, morphologic changes, functional capacity and quality of life relative to control. CA should be considered in patients with AF and HF. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12872-018-0904-3) contains supplementary material, which is available to authorized users. BioMed Central 2018-08-13 /pmc/articles/PMC6090632/ /pubmed/30103676 http://dx.doi.org/10.1186/s12872-018-0904-3 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Ma, Yingxu
Bai, Fan
Qin, Fen
Li, Yixi
Tu, Tao
Sun, Chao
Zhou, Shenghua
Liu, Qiming
Catheter ablation for treatment of patients with atrial fibrillation and heart failure: a meta-analysis of randomized controlled trials
title Catheter ablation for treatment of patients with atrial fibrillation and heart failure: a meta-analysis of randomized controlled trials
title_full Catheter ablation for treatment of patients with atrial fibrillation and heart failure: a meta-analysis of randomized controlled trials
title_fullStr Catheter ablation for treatment of patients with atrial fibrillation and heart failure: a meta-analysis of randomized controlled trials
title_full_unstemmed Catheter ablation for treatment of patients with atrial fibrillation and heart failure: a meta-analysis of randomized controlled trials
title_short Catheter ablation for treatment of patients with atrial fibrillation and heart failure: a meta-analysis of randomized controlled trials
title_sort catheter ablation for treatment of patients with atrial fibrillation and heart failure: a meta-analysis of randomized controlled trials
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6090632/
https://www.ncbi.nlm.nih.gov/pubmed/30103676
http://dx.doi.org/10.1186/s12872-018-0904-3
work_keys_str_mv AT mayingxu catheterablationfortreatmentofpatientswithatrialfibrillationandheartfailureametaanalysisofrandomizedcontrolledtrials
AT baifan catheterablationfortreatmentofpatientswithatrialfibrillationandheartfailureametaanalysisofrandomizedcontrolledtrials
AT qinfen catheterablationfortreatmentofpatientswithatrialfibrillationandheartfailureametaanalysisofrandomizedcontrolledtrials
AT liyixi catheterablationfortreatmentofpatientswithatrialfibrillationandheartfailureametaanalysisofrandomizedcontrolledtrials
AT tutao catheterablationfortreatmentofpatientswithatrialfibrillationandheartfailureametaanalysisofrandomizedcontrolledtrials
AT sunchao catheterablationfortreatmentofpatientswithatrialfibrillationandheartfailureametaanalysisofrandomizedcontrolledtrials
AT zhoushenghua catheterablationfortreatmentofpatientswithatrialfibrillationandheartfailureametaanalysisofrandomizedcontrolledtrials
AT liuqiming catheterablationfortreatmentofpatientswithatrialfibrillationandheartfailureametaanalysisofrandomizedcontrolledtrials